Sabra Healthcare REIT Inc [SBRA] stock prices are down -0.18% to $16.39 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The SBRA shares have lost -0.97% over the last week, with a monthly amount drifted -6.02%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Sabra Healthcare REIT Inc [NASDAQ: SBRA] stock has seen the most recent analyst activity on January 17, 2025, when Truist downgraded its rating to a Hold. Previously, JMP Securities upgraded its rating to Mkt Outperform on January 07, 2025, and kept the price target unchanged to $20. On December 05, 2024, downgrade downgraded it’s rating to Neutral but maintained its price target of $20 on the stock. Wells Fargo upgraded its rating to a Overweight and increased its price target to $20 on October 01, 2024. Citigroup upgraded its rating to a Buy and raised its price target to $20 on September 13, 2024. Deutsche Bank started tracking with a Buy rating for this stock on January 30, 2024, and assigned it a price target of $21. In a note dated October 17, 2023, BMO Capital Markets downgraded an Market Perform rating on this stock but restated the target price of $16.
The stock price of Sabra Healthcare REIT Inc [SBRA] has been fluctuating between $13.22 and $19.99 over the past year. Currently, Wall Street analysts expect the stock to reach $19 within the next 12 months. Sabra Healthcare REIT Inc [NASDAQ: SBRA] shares were valued at $16.39 at the most recent close of the market. An investor can expect a potential return of 15.92% based on the average SBRA price forecast.
Analyzing the SBRA fundamentals
The Sabra Healthcare REIT Inc [NASDAQ:SBRA] reported sales of 701.05M for trailing twelve months, representing a surge of 5.18%. Gross Profit Margin for this corporation currently stands at 0.58% with Operating Profit Margin at 0.27%, Pretax Profit Margin comes in at 0.18%, and Net Profit Margin reading is 0.18%. To continue investigating profitability, this company’s Return on Assets is posted at 0.02, Equity is 0.05 and Total Capital is 0.06. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.64.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 16.30 points at the first support level, and at 16.22 for the second support level. However, for the 1st resistance point, the stock is sitting at 16.53, and for the 2nd resistance point, it is at 16.68.
Ratios To Look Out For
Considering the valuation of this stock, the price to sales ratio is 5.56, the price to book ratio is 1.42 and price to earnings (TTM) ratio is 30.60.
Transactions by insiders
Recent insider trading involved Cusack Catherine, Director, that happened on Feb 24 ’25 when 1500.0 shares were purchased. Director, Cusack Catherine completed a deal on Feb 21 ’25 to buy 1000.0 shares. Meanwhile, Director Cusack Catherine bought 7000.0 shares on May 22 ’24.
